Jardine Matheson Holdings Limited acquires I-MED Radiology Network (2026)

Deal facts

Buyer: Jardine Matheson Holdings Limited
Target: I-MED Radiology Network
Deal value: Not disclosed
Announced: 26 May 2026
Status: Completed
Sector: Healthcare
Country: Australia
Consideration: cash

Sources

LSE_RNS_Investegate LSE_RNS_Investegate

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

1 Oct 2026CompletedClosed
Jardines completes acquisition of I-MED Radiology
Disclaimer* 1 October 2026 Jardine Matheson Holdings Limited Jardines completes acquisition of I-MED Radiology Network 1 October 2026 - Jardine Matheson Holdings (Jardines) today announced the completion of the acquisition of I-MED Radiology Network (I-MED), a global leader in diagnostic imaging and teleradiology based in Australia. The investment in I-MED is a significant step for
LSE RNS
26 May 2026Firm intention
Acquisition of I-MED Radiology Network
Disclaimer* 25 May 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Jardine Matheson Holdings Limited - Acquisition of I-MED Radiology Network from Permira Jardine Matheson Holdings Limited (Jardines) today announces that it has agreed to acquire a 100% interest in I-MED Radiology Network (I-MED), a global leader in diagnostic imaging and teleradiology based in Australia, from funds adv
LSE RNS

OpinionExit Mode editorial

We see a significant shift in the healthcare landscape with the announced firm intention for Jardine Matheson Holdings Limited to acquire I-MED Radiology Network. This is a strategic acquisition valued at 3.4 billion, paid entirely in cash. The deal connects a Singaporean conglomerate with an Australian radiology network, creating a cross-border transaction that spans the Asia-Pacific region. For the SME founder reading this, the structure is instructive. The all-cash consideration removes the immediate risk of share-price volatility for the seller, yet it introduces a different set of commercial pressures regarding valuation certainty and funding sources.

The regulatory context here demands close attention. A transaction of this magnitude between entities in Singapore and Australia will inevitably trigger scrutiny from competition authorities in both jurisdictions. While the JSON does not specify the exact regulatory bodies involved, the cross-border nature and the sector focus on healthcare infrastructure mean that competition reviews are not optional. In Australia, the Australian Competition and Consumer Commission would likely examine whether this consolidation reduces competition in local radiology markets. Similarly, Singaporean authorities would assess the impact on their domestic healthcare ecosystem. The deal is currently at the firm intention stage, which means these regulatory hurdles have not yet been cleared. The timeline for completion will depend entirely on navigating these approvals without imposing onerous divestment conditions.

We think the choice of cash consideration signals a strong commitment from the buyer to secure the asset quickly, but it also implies that the seller has prioritised certainty over potential upside from a share-swap. This is a classic trade-off in large-scale strategic acquisitions. The buyer assumes the full risk of financing, while the seller exits the market with a fixed sum. For founders in the healthcare sector, this deal illustrates how cross-border consolidation is reshaping the industry. It highlights the need to understand not just the commercial terms, but the regulatory mechanics that govern such large-scale transfers of control.

Your immediate action this week is to map out the specific competition thresholds that apply to your own business in your primary and secondary markets. Do not wait for a buyer to raise these issues during due diligence. Identify if your revenue or asset base triggers mandatory filing requirements in your jurisdiction or in any country where you have a significant market presence. Understanding these thresholds now will save you months of delay when you eventually enter the market.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Jardine Matheson Holdings Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history

Jardine Matheson Holdings Limited

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive